Based on our finding that 87.5% (7 out of 8) of patients with FOXO1 mutations are EBV-positive, we consider that FOXO1 may be a key mutation driven by EBV infection and could be a crucial factor in the progression of EBV-positive BL. Here, FOXO1 is linked to Burkitt lymphoma.